NeuroPace, Inc. 10-Q Summary
Business Context and Reporting Period
NeuroPace is a commercial-stage medical device company focused on its RNS System, a brain-responsive neuromodulation system for adults with drug-resistant focal epilepsy. The company manufactures and distributes the system from Mountain View, California, and sells exclusively in the United States. This unaudited Form 10-Q covers the three months ended March 31, 2022, compared with the three months ended March 31, 2021.
Key Financial Metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | $11.4 million | $11.2 million | Up 1% |
| Gross profit | $8.3 million | $8.5 million | Down 3% |
| Gross margin | 72.6% | 75.7% | Down 310 basis points |
| Research and development | $5.6 million | $4.1 million | Up 36% |
| SG&A | $12.4 million | $8.3 million | Up 51% |
| Loss from operations | $(9.8) million | $(3.9) million | Loss increased |
| Net loss | $(11.5) million | $(8.8) million | Loss increased 30% |
| Net loss per share | $(0.47) | $(32.73) | Not directly comparable after IPO |
| Cash used in operating activities | $(11.4) million | $(5.9) million | Use increased |
| Cash, cash equivalents and short-term investments | $103.2 million | $115.6 million at Dec. 31, 2021 | Down $12.4 million |
| Term loan, net | $50.1 million | $49.8 million at Dec. 31, 2021 | Up $0.3 million |
At March 31, 2022, total assets were $129.0 million, current liabilities were $12.1 million, total liabilities were $66.2 million, and accumulated deficit was $435.2 million. The company had $7.5 million of cash and cash equivalents and $95.7 million of short-term investments. Comprehensive loss was $12.2 million, including a $0.7 million unrealized loss on available-for-sale debt securities.
Material Changes Versus the Prior Comparable Period
- Revenue increased modestly, primarily because of higher initial-implant unit volume. Replacement procedures represented approximately 23% of revenue versus 28% in the prior-year quarter.
- Gross margin declined because of higher indirect labor costs and lower production volume associated with COVID-19-related procedure volatility, particularly the Omicron variant.
- Research and development costs rose primarily from additional personnel, product development, and clinical-study spending.
- SG&A increased due to hiring, higher stock-based compensation, public-company costs, and increased sales, field-support, and marketing activity.
- Operating cash use nearly doubled, reflecting the larger net loss and a $2.0 million increase in accounts receivable, partly offset by noncash expenses.
- The $3.1 million unfavorable fair-value adjustment recorded in other expense in Q1 2021 did not recur because the preferred-stock warrant liability was converted and reclassified in connection with the April 2021 IPO.
- Effective January 1, 2022, the company adopted ASC 842 for leases, recognizing a $6.1 million right-of-use asset and $7.5 million of lease liabilities at adoption. The adoption did not affect earnings or cash flows.
- Stock-based compensation increased to $1.5 million from $0.2 million. Unrecognized stock-based compensation was $27.3 million at March 31, 2022, excluding approximately $0.1 million related to the employee stock purchase plan.
Liquidity, Debt, Guidance and Outlook
Management believes cash, cash equivalents, and short-term investments will fund planned operations for at least 12 months from issuance of the interim financial statements. The company nevertheless expects continued net losses and negative operating cash flow for the next several years and may require additional equity or debt financing.
The $50.0 million term loan bears interest at 12.5%, has an effective annual interest rate of approximately 15.66%, is secured by substantially all company assets including intellectual property, and requires a 10% backend repayment fee. The interest-only period was extended through September 30, 2025, with principal due in one installment thereafter. The $10.0 million undrawn portion expired because a 2021 revenue milestone was not achieved.
The loan requires minimum annual net revenue of $43.0 million for 2022 and minimum cash and cash equivalents of $5.0 million. NeuroPace stated that it was in compliance with all loan covenants at March 31, 2022. Failure to meet future covenants could permit the lender to accelerate the debt and create a need for additional funding.
No formal revenue or earnings guidance is provided in the filing. Management expects to continue investing in commercial expansion, research and development, clinical studies, regulatory activities, and potential indication expansion to adolescents and patients with generalized epilepsy. The company also expects continued public-company expenses and does not expect profitability in the near term.
Risks, Contingencies and Unusual Items
- COVID-19, including the Omicron variant, reduced elective procedures, epilepsy diagnostic evaluations, hospital capacity, and staffing availability. Future procedure volumes and the timing of recovery remain uncertain.
- The company depends substantially on one product, one U.S. market, and adoption at a limited number of Level 4 comprehensive epilepsy centers.
- NeuroPace relies on several single-source suppliers, including suppliers of critical components such as batteries and printed circuit assemblies.
- The company faces regulatory, clinical, reimbursement, product-liability, intellectual-property, cybersecurity, and data-privacy risks typical of an implantable medical-device business.
- Replacement revenue may decline over the next several years because the current neurostimulator has an expected average battery life of nearly 11 years, versus the prior assumption of eight years.
- The company is cooperating with CFIUS regarding an inquiry received in April 2021 and cannot predict the outcome.
- A stockholder lawsuit alleges claims related to the company’s reverse stock splits. NeuroPace believes the claims lack merit; no loss estimate or range can currently be made.
- The company reported that a material weakness in internal control over financial reporting identified as of December 31, 2021 was remediated by March 31, 2022. Disclosure controls and procedures were considered effective at the reasonable-assurance level.
- Future minimum operating-lease payments were $7.3 million at March 31, 2022, with the principal facility lease expiring in June 2024.
Important Facts for Investors to Verify
- Whether revenue growth and initial-implant volumes accelerate as COVID-19-related hospital restrictions and staffing constraints ease.
- Whether the company can achieve the $43.0 million 2022 minimum revenue covenant while maintaining at least $5.0 million of cash and cash equivalents.
- The rate of operating cash burn and the estimated duration of the company’s $103.2 million liquidity balance.
- Progress toward FDA label expansion for adolescent and generalized epilepsy indications and the associated clinical-study costs and timelines.
- The effect of the longer battery life on replacement-procedure revenue and gross margin.
- Any developments in the CFIUS inquiry, stockholder litigation, regulatory matters, product liability, or intellectual-property disputes.
- Whether increased sales and marketing, research and development, and public-company costs translate into sustainable revenue growth and improved operating leverage.